Your consultation is an opportunity to discuss with your retina specialist how your current treatment fits into your schedule, and whether SUSVIMO may be the right fit for you.
You and your retina specialist will discuss your vision history
They will check that you’ve previously received at least two intravitreal eye injections of a vascular endothelial growth factor (VEGF) inhibitor that have worked for you
To support your conversation with your retina specialist, you can download our Doctor Conversation Guide here
After you and your retina specialist decide SUSVIMO is right for you, next steps could include:
Arranging for someone to bring you to and from your surgical procedure
Talking with your retina specialist about what to expect during, and after the procedure
Getting SUSVIMO is a short, one-time, outpatient procedure.
The procedure typically takes about 30 minutes
Your eye will be treated with local anesthesia to help you feel comfortable
Placing SUSVIMO requires only 1 small incision (3.5 mm)
SUSVIMO is placed underneath your eyelid, in the white part of your eye
You’ll be able to go home the same day
Your retina specialist will schedule follow-up appointments to check on your recovery and make sure your eye is healing properly.
Typically, people can return to most normal activities soon after the procedure
Do not participate in strenuous activities until 1 months after your implant procedure or after talking to your healthcare provider
For more information, you can download our Procedure Guide here
Positioning for your head
Keep your head above shoulder level for the rest of the day
Sleep with your head on 3 or more pillows if lying down during the day and night after your implant procedure
How to care for your eye
Do not remove the eye shield from your eye until you are told to by your healthcare provider. At bedtime, continue to wear an eye shield for at least 7 nights following your implant procedure
Take all post-operative eye medicines as your healthcare provider tells you to
Do not push on your eye, rub your eye, or touch the area of your eye where your implant is located (underneath your eyelid in the upper and outer part of your eye) for 30 days following your implant procedure
You and your retina specialist will schedule refill appointments every 9 months:*
The refill goes directly into your SUSVIMO implant
Follow the instructions provided by your retina specialist
Don’t push on your eye, rub your eye, or touch the area of your implant for 7 days after your refill - this is the area underneath your upper eyelid and outer part of your eye
Take antimicrobial eye drops as prescribed by your retina specialist
Notify your primary eye doctor or retina specialist immediately if you notice redness, sensitivity to light, pain, or a change in your vision. These are signs of an infection inside the eye called endophthalmitis
If your retina specialist determines that it is necessary, you may need an anti-VEGF injection in the gel-like part of the SUSVIMO-treated eye (intravitreal) before your next refill.
There is more to know about preparation and post-procedure care for the implant procedure and refills, refer to the Medication Guide (the section titled "How will I receive SUSVIMO?") for important instructions.
Seek immediate care from your retina specialist if there are:
Sudden changes in your vision (an increase in moving spots, the appearance of “spider webs”, flashing lights, or a loss in vision)
Increasing eye pain
Progressive vision loss
Sensitivity to light
Increasing redness in the white of the eye
A sudden sensation that something is in your eye
Eye discharge or watering
Patient has been compensated by Genentech. Patient experiences may vary.
Please see the video for more information about side effects, including the risk of endophthalmitis.
YOUR DOCTOR CONVERSATION GUIDE
Answer a few questions to get your personalized conversation guide. Ask your retina specialist if SUSVIMO is right for you.
SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.
SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.
Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126:1141-1154.
Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126:1141-1154.
SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.
SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.
Monés J, Gune S, Maia M, et al. Pharmacokinetic profile of the port delivery system with ranibizumab in the phase 3 Archway trial. Presented at 21st EURETINA Congress, September 9-12, 2021.
Monés J, Gune S, Maia M, et al. Pharmacokinetic profile of the port delivery system with ranibizumab in the phase 3 Archway trial. Presented at 21st EURETINA Congress, September 9-12, 2021.
Ranade SV, Wieland MR, Tam T, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Delivery. 2022;29(1):1326-1334.
Ranade SV, Wieland MR, Tam T, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Delivery. 2022;29(1):1326-1334.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Holekamp NM, Campochiaro PA, Chang MA, et al; Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295-307.
Holekamp NM, Campochiaro PA, Chang MA, et al; Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295-307.
A phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration. ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934
A phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration. ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934
Wykoff CC; Archway Investigators. 2-year outcomes from the phase 3 Archway trial: management of neovascular age-related macular degeneration using the port delivery system with ranibizumab (PDS). Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition, February 11-12, 2022.
Wykoff CC; Archway Investigators. 2-year outcomes from the phase 3 Archway trial: management of neovascular age-related macular degeneration using the port delivery system with ranibizumab (PDS). Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition, February 11-12, 2022.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmology. Published online June 16, 2022.
Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmology. Published online June 16, 2022.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.